poisar

Stocks · News reference

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Benzinga Newsdesk

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LRMR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Larimar Therapeutics, Inc. (LRMR)

    Filed: 2026-09-29 AccNo: 0001193125-26-407331 Size: 156 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

    LRMR
  3. Benzinga Newsdesk

    Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate

    Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share

    LRMR